Columbia Labs (CBRX) Issues Significant Data for Progesterone in Reducing Preterm Birth, Neonatal Morbidity

Columbia Laboratories, Inc. (Nasdaq: CBRX) reports that a meta-analysis of data from five double-blind, placebo-controlled trials of vaginal progesterone, including the PREGNANT study, Columbia's pivotal clinical trial of progesterone vaginal gel 8% to reduce the risk of preterm birth in women with premature cervical shortening, found that administering vaginal progesterone to asymptomatic women with a sonographic short cervix in the mid-trimester of pregnancy significantly reduces the risk of preterm birth and neonatal morbidity.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• loanDepot (LDI) Appoints Jeff Wilkish as Regional VP for New England
• Rollins (ROL) Appoints Louise S. Sams to its Board